Edesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo

Edesa Biotech, Inc. (Nasdaq: EDSA) has received FDA clearance for its Investigational New Drug application for a Phase 2 clinical trial of EB06 in vitiligo, allowing the company to expand patient recruitment to the U.S. Recruitment is currently underway in Canada, with U.S. investigational sites expected to start enrolling subjects next quarter. Edesa anticipates topline data from the trial will be available in the fourth quarter of 2027.